Socioeconomic Inequality in the Use of Rituximab Therapy Among Non-Hodgkin Lymphoma Patients in Chinese Public Hospitals
Background. Rituximab is a patient-paid effective monoclonal-antibody drug for non-Hodgkin lymphoma (NHL). Little is known in China, a country with unequal distribution of wealth and medical insurance systems, about the impact of socioeconomic status (SES) on selecting rituximab therapy in NHL patie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Sage Publications, Inc.
2012
|
| Online Access: | http://hdl.handle.net/20.500.11937/44224 |